12:05 PM EDT, 10/20/2025 (MT Newswires) -- The European stock markets closed mostly higher in Monday trading as the Stoxx Europe 600 climbed 1.06%, Germany's DAX surged 1.93%, the FTSE 100 was up 0.52%, France's CAC 0.43% higher, while the Swiss Market Index edged 0.07% lower.

In the UK, The S&P Global UK Consumer Sentiment Index declined to 47.4 in October from 47.8 in September, however it was the second-highest reading since July 2024 and above the long-run average.

"The autumn is seeing some of the gloom lift from UK households," Maryam Baluch, an economist at S&P Global Market Intelligence, said in a statement. "However, it's clear the cost of living crisis has not yet been beaten."

In Germany, annual producer prices for industrial products fell 1.7% in September, and were off 0.1% on a monthly base, according to the Federal Statistical Office.

And in corporate news, Stellantis Chief Executive Officer Antonio Filosa is to meet with Italian labor unions Monday, as the carmaker has paused production at several factories, Bloomberg News reported Monday. The unions want clarity on Filosa's intentions for car manufacturing in Italy, and on plans for the ailing Maserati brand, according to the report.

Stellantis did not immediately respond to MT Newswires' request for comment on the matter.

Shares of the automaker added 2.3% in Paris.

Amgen and AstraZeneca said late Friday the US Food and Drug Administration has approved Tezspire for the add-on maintenance treatment of inadequately controlled chronic rhinosinusitis with nasal polyps in adult and pediatric patients aged 12 years and older. The approval was based on efficacy and safety data from the late-stage WAYPOINT trial, the companies said, adding that regulatory applications are under review in Europe, China, Japan and several other countries.

Shares of AstraZeneca were fractionally higher in London on the FTSE 100.

Adaptimmune Therapeutics said Monday that it will voluntarily delist its American depositary shares from the Nasdaq Capital Market and begin the process to deregister from US Securities and Exchange Commission reporting. The decision comes after Adaptimmuned received a Nasdaq notice giving the company until Dec. 1 to regain compliance with the $1 minimum bid price rule, which it is unlikely to meet, the company said.

Shares of the biopharmaceutical company gained 6.6% in Frankfurt.

Smith & Nephew's risk-reward profile remains "skewed to the upside" as the company transitions from recovery mode to growth delivery, RBC Capital Markets said in a Monday note previewing the company's Capital Markets Day in December. Upcoming guidance is expected to include a compound annual revenue growth rate of 5% to 6%, with Sport Medicine being a primary driver of mid-term growth, bolstered by steady progress in Wound Care and moderate growth in Orthopedics, according to the note.

RBC reiterated the company' stock rating at outperform and raised the price target to 17 British pounds ($22.8) from 14 pounds.

Shares of the medical device maker increased 0.7% in London.